<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733171</url>
  </required_header>
  <id_info>
    <org_study_id>4940</org_study_id>
    <nct_id>NCT03733171</nct_id>
  </id_info>
  <brief_title>Platelet Rich Plasma in Bleeding Peptic Ulcer</brief_title>
  <acronym>PRP</acronym>
  <official_title>Role of Platelet Rich Plasma in the Treatment of Actively Bleeding Peptic Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most common cause of acute upper gastrointestinal bleeding (UGIB) is non-variceal, where&#xD;
      peptic ulcer bleeding (PUB) remains the single most common cause, accounting for 25% to 67%&#xD;
      of the causes of non-variceal upper gastrointestinal bleeding (NVUGIB).&#xD;
&#xD;
      Despite major advances in diagnostic and therapeutic tools, PUB remains a significant problem&#xD;
      and an important cause of morbidity and mortality. Given the imperative therapeutic role of&#xD;
      endoscopic management in achieving hemostasis in NVUGIB, new modalities to improve the&#xD;
      current treatment strategies continue to be developed.&#xD;
&#xD;
      Platelet-rich plasma (PRP) is a widely used throughout many fields of medicine for improving&#xD;
      tissue regeneration. PRP contains a higher concentration of platelets than whole blood, and&#xD;
      represents a pool of many growth-factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients were subjected to full history taking, complete clinical examination, laboratory&#xD;
      investigations (complete blood count, liver and kidney function tests, coagulation profile),&#xD;
      ECG and Upper GI endoscopy was performed within 24 hours of hospital admission after initial&#xD;
      resuscitation of patients including blood transfusion if HB level ≤ 7g ∕ L.&#xD;
&#xD;
      Stigmata of recent hemorrhage was defined according to the Forrest (F) classification (FIa-&#xD;
      spurting hemorrhage, FIb- oozing hemorrhage, FIIa- non-bleeding visible vessel, FIIb-&#xD;
      adherent clot, FIIc- flat pigmented spot and FIII- clean base ulcer).The size of an ulcer was&#xD;
      classified as &lt; 2 cm or ≥ 2cm.&#xD;
&#xD;
        -  PRP or diluted epinephrine were injected in 1-2 ml by multiple injections into and&#xD;
           circumferentially around the ulcer until bleeding stopped using a 25-G retractable,&#xD;
           standard sclerotherapy needle.&#xD;
&#xD;
        -  Group I was subjected to multiple injection of PRP (each 1-2 ml), while group II was&#xD;
           subjected to epinephrine injections (each 1-2 ml of a 1:10.000 solution of epinephrine)&#xD;
           .&#xD;
&#xD;
        -  Hemostasis was achieved if bleeding stopped for at least 3 min of observation.&#xD;
           Immediately after the endoscopic hemostasis, PPIs were infused at a standard regimen (40&#xD;
           mg bolus of PPI once daily for 72 h) or at a high-dose regimen (loading dose of 80 mg on&#xD;
           the first day followed by continuous infusion of 8 mg/h for 72 h), after the initial 72&#xD;
           h, patients were switched to oral PPIs (20 mg twice daily) until discharge .&#xD;
&#xD;
      PRP preparation method&#xD;
&#xD;
      Under complete aseptic conditions the blood was drawn with the addition of anticoagulant such&#xD;
      as citrate dextrose A to prevent platelet activation prior to its use.&#xD;
&#xD;
      1.30-60 cc of patients' blood drawn at the time of treatment by venipuncture in acid citrate&#xD;
      dextrose (acts as an anticoagulant) tubes 2. Do not chill the blood. 3. Centrifuge the blood&#xD;
      using a 'soft' spin (1st centrifugation). 4. Transfer the supernatant plasma containing&#xD;
      platelets into another sterile tube (without anticoagulant).&#xD;
&#xD;
      5. Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate (2nd&#xD;
      centrifugation).&#xD;
&#xD;
      6. The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the&#xD;
      tube, platelet pellets are formed.&#xD;
&#xD;
      7. Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by&#xD;
      gently shaking the tube.&#xD;
&#xD;
      8.Thrombin (dose) was added to activate PRP&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bleeding</measure>
    <time_frame>3 months</time_frame>
    <description>control of peptic ulcer bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improved iron indices</measure>
    <time_frame>3 months</time_frame>
    <description>imroved complete blood count element</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bleeding Ulcer</condition>
  <arm_group>
    <arm_group_label>Platelet rich plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>endoscopic injection of PRP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>diluted epinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLATELET RICH PLASMA</intervention_name>
    <description>PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle</description>
    <arm_group_label>Platelet rich plasma</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diluted epinephrine</intervention_name>
    <description>diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle</description>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <other_name>Hemostasis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemoclips</intervention_name>
    <description>diluted epinephrine was injected followed by application of hemoclips</description>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <other_name>mechanical hemostasis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have a peptic ulcer with either actively bleeding or a non-bleeding&#xD;
             visible vessel&#xD;
&#xD;
          -  initial hemoglobin concentration of &lt; 10 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with non-PUB, coagulopathy, bleeding disorders, anticoagulant therapy,&#xD;
             cardiopulmonary compromise, hypertension, ischemic heart disease, arrhythmia, and&#xD;
             patients who refused to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WASEEM SELEEM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>zagazig university hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Waseem Seleem, MD</last_name>
    <phone>+201026258004</phone>
    <email>WASEEMMOHAMED1975@GMAIL.COM</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amr Hanafy, md</last_name>
    <phone>+201100061861</phone>
    <email>dr_amr_hanafy@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zagazig University</name>
      <address>
        <city>Zagazig</city>
        <state>Sharkia</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waseem Seleem, md</last_name>
      <phone>+201025264008</phone>
      <email>waseemmohamed1975@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Amr Hanafy, md</last_name>
      <phone>+201100061861</phone>
      <email>dr_amr_hanafy@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Amr Shaaban Hanafy</investigator_full_name>
    <investigator_title>Assistant professor of medicine</investigator_title>
  </responsible_party>
  <keyword>platelet rich plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Peptic Ulcer Hemorrhage</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

